Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis

<i>Background</i>: Patients with refractory metastatic colorectal cancer (mCRC) rarely receive third-line or further treatment. In this context, regorafenib (R) and trifluridine/tipiracil (T) are two important novel therapeutic choices with statistically significant increases in overall...

Full description

Bibliographic Details
Main Authors: Carlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, Michele Basso, Maria Alessandra Calegari, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
metastatic colorectal cancer
regorafenib
trifluridine/tipiracil
first drug treatment duration
sequential treatment
third-line therapy
Online Access:https://www.mdpi.com/2072-6694/15/24/5758

Internet

https://www.mdpi.com/2072-6694/15/24/5758

Similar Items